We are entering an era of unprecedented complexity in personalized medicine. Therapeutic targets, biomarker detection technologies, regulatory and reimbursement pathways, and commercialization strategies have all reached new levels of intricacy. These complexities are occurring in the context of the current economic environment, in which outsourcing offers a way for innovators to decrease large internal investment. These factors combine to create a perfect setting for a partnership explosion. Now, and as we move into the future, it will be critical for innovators to access outside expertise with a diverse set of partners in order to bring novel personalized medicine products to the market successfully and economically. Only companies that truly embrace this trend and adopt a collaborative approach will emerge successful.
Keywords: commercialization; diagnostics; life science; oncology; outsourcing; partnership; personalized medicine; targeted therapy.